Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis

✍ Scribed by Gil I. Wolfe; Richard J. Barohn; Barbara M. Foster; Carlayne E. Jackson; John T. Kissel; John W. Day; Charles A. Thornton; Sharon P. Nations; Wilson W. Bryan; Anthony A. Amato; Miriam L. Freimer; Gareth J. Parry

• Publisher: John Wiley and Sons
• Year: 2002
• Tongue: English
• Weight: 80 KB
• Volume: 26
• Category: Article
• ISSN: 0148-639X
• DOI: 10.1002/mus.10224

✦ Synopsis

Abstract

We initiated a randomized, double‐blinded, placebo‐controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6‐week open‐label study of IVIG, positive trends were observed. © 2002 Wiley Periodicals, Inc. Muscle Nerve 26: 549–552, 2002